Icon (ICLR)

ICON’s services cover a broad range of clinical research activities. These include trial planning, site selection, patient recruitment, clinical monitoring, data management, biostatistics, laboratory services, pharmacovigilance and regulatory consulting. By outsourcing this work to a CRO, drug developers can access global infrastructure, specialised expertise and scalable trial operations without building every capability in-house.

The company is particularly important in late-stage clinical development, where trials can involve many sites, large patient populations and complex regulatory requirements. ICON also supports decentralised and technology-enabled trial models, using data, digital tools and analytics to improve recruitment, monitoring and decision-making. Its postmarket work can help clients gather evidence on safety, effectiveness and real-world use after a product is approved.

ICON competes in a large CRO industry driven by pharmaceutical research spending, biotech innovation, regulatory complexity and the need to bring medicines to market efficiently. Its global employee base and presence across dozens of countries give it the scale to manage multinational studies and navigate local clinical and regulatory environments. The company’s role is to reduce operational burden for sponsors while helping maintain quality, compliance and scientific rigour throughout the development process.